Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ligand Pharmaceuticals reports stellar Q4 earnings and growth prospects

Ligand Pharmaceuticals demonstrated robust financial performance in Q4 2022, driven by strong royalty revenue growth and strategic initiatives.
While facing challenges in cost optimization and label expectations, Ligand's focus on operational efficiency and growth opportunities positions it well for the future.
With a solid financial foundation, a diverse portfolio of assets, and a commitment to strategic growth, Ligand is poised for continued success and value creation.

Ligand Pharmaceuticals excels in Q1, eyes growth through strategic assets

Ligand Pharmaceuticals delivered robust Q1 results, positioning itself for continued growth and financial stability.
The company's strategic focus on high-quality assets, diversification, and efficient deal execution underscores its commitment to driving value for investors.
Despite market challenges, Ligand remains optimistic, leveraging opportunities in the biopharmaceutical sector to sustain growth and enhance shareholder value.

Ligand Pharmaceuticals excels in Q2, eyes strategic growth opportunities

Ligand Pharmaceuticals delivered a robust performance in Q2 2023, driven by strong revenue growth and strategic financial moves.
While facing challenges in contract revenue and competitive markets, Ligand's focus on key products and acquisitions signals resilience and adaptability.
Opportunities lie in expanding revenue streams, navigating market dynamics, and leveraging FDA developments for future growth.

Ligand Pharmaceuticals reports robust Q3 earnings and strategic investments

Ligand Pharmaceuticals showcased strong financial performance, strategic investments in late-stage products, and a focus on revenue growth and portfolio management. Despite challenges in clinical trials and market estimations, the company's emphasis on growth and investor engagement presents opportunities for future success.

Ligand Pharmaceuticals reports robust Q4 earnings and strategic growth moves

Ligand Pharmaceuticals showcased a strong financial performance in Q4 2023, with strategic business streamlining and portfolio enhancements driving growth. Despite supply constraints related to a predecessor product, successful collaborations have ensured manufacturing readiness for key products like Rylaze. The company's diversified portfolio and strong partnerships position it well for continued growth and shareholder returns in 2024.

Ligand Pharmaceuticals reports robust Q1 performance and strategic investments

Ligand Pharmaceuticals shows strong financial performance and growth potential, supported by strategic partnerships and key developments in their portfolio.
While facing challenges like upcoming generic competition and revenue uncertainty from recent deals, the company remains focused on long-term growth.
Opportunities lie in projected revenue and EPS growth, market expansion for Filspari, and continued interest in licensing for revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True?

Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.

Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors

Ligand (LGND) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now?

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time. Management will participate in one-on-one investor meetings during the conference. Investors interested in meeting with Ligand should contact their Barclays repres.

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand's Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee. The grant date for the options was March 1, 2024. The award was granted under Ligand's 2022 Employment Inducement Plan, as amended (the “Inducement Plan”) as an employment inducem.

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest?

Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.

Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges

Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “2023 was a transformative year for Ligand, both operationally and financially. We refocused the company to be a lean-infr.

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible. Fycompa is formulated with Captisol®, a Ligand technology. Fyco.

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Ligand Pharmaceuticals (LGND) reachead $72.37 at the closing of the latest trading day, reflecting a -1.75% change compared to its last close.

Why Ligand Pharmaceuticals (LGND) Dipped More Than Broader Market Today

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments. Both executives will report to CEO Todd Davis. “Rich and Karen strengthen our commercial and clinical bench, better positioning us to capitalize on this exciting period in the life sciences industry,” said Todd Davis, CEO.

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Tuesday, February 27, 2024, and will hold a conference call at 8:30 a.m. Eastern Time that same day to discuss financial results and provide a general business update. Conference Call and Webcast Information Date:   Tuesday, February 27, 2024 Time:   8:30 a.m. Eastern Time (5:30.

Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $75.64, marking a -0.32% move from the previous day.

Here's Why Ligand Pharmaceuticals (LGND) Fell More Than Broader Market

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, today announced the publication of research in Nature Machine Intelligence showing that its NeuralPLexer technology outperforms other state-of-the art systems in predicting the structure of protein-ligand complexes as well as the conformational changes to these structures from the addition of drug molecules. “Our benchmarking shows we have set.

Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $74.72, denoting a +0.24% change from the preceding trading day.

Ligand Pharmaceuticals (LGND) Advances While Market Declines: Some Information for Investors

Ligand Pharmaceuticals (LGND) closed at $72.19 in the latest trading session, marking a -1.84% move from the prior day.

Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key Insights

Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.

Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel

Ligand Pharmaceuticals' topical treatment for a viral skin infection has received approval from the U.S. health regulator, the company said on Friday, marking the first-ever at-home approved treatment for the condition in the country.

Ligand Pharma's at-home skin treatment gets FDA approval

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections. ZELSUVMI is the first and only topical prescription medication that can be applied by patie.

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Arlo Technologies Inc

Catalyst Pharmaceuticals

Digi

Dynavax Technologies

Green Plains

Helix Energy Solutions Group

Ironwood Pharma

Livent Corp

ModivCare

Payoneer Global

Pacira Pharmaceuticals

Patterson-UTI Energy

Arcus Biosciences

SMART Global Hlds

Talos Energy Inc

Vir Biotechnology

Xencor

Xperi

The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized companies have also rallied, but not as much:

20 favorite small-cap stocks for 2024 among Wall Street analysts

Ligand Pharmaceuticals (LGND) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, LGND crossed above the 200-day moving average, suggesting a long-term bullish trend.

Ligand Pharmaceuticals (LGND) Just Overtook the 200-Day Moving Average

Ligand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years.

Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand's senior management team provided an overview of the company's business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance. A copy of the presentation and a replay of the webcast are available at investor.ligand.c.

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

News for Ligand Pharmaceuticals Stock (LGND)